These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19803010)

  • 1. Ceftazidime: therapeutic results in various infections and kinetic studies.
    Daikos GK; Kosmidis J; Stathakis C; Giamarellou H; Douzinas E; Kastanakis S; Papathanassiou B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():331-7. PubMed ID: 19803010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime in serious hospital-acquired infections.
    Hoogkamp-Korstanje JA; van Erpecum KJ; van Kamp H
    J Antimicrob Chemother; 1985 Jun; 15(6):743-9. PubMed ID: 3897167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation between pulmonary pharmacokinetics and pharmacodynamics support the hypothesis of the usefulness of ceftazidime at a single 1g daily dose in the treatment of bacterial exacerbation of chronic obstructive bronchopneumonia with moderate functional damage].
    Cazzola M; Noschese P; Vinciguerra A; Di Perna F; Califano C; Berra A
    Minerva Med; 1998; 89(1-2):15-22. PubMed ID: 9561021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.
    Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC
    J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of complicated urinary tract infection caused by Pseudomonas aeruginosa--a comparison of the efficacy of ceftazidime with that of netilmicin.
    Graninger W; Ho I; Francesconi M; Schmidbauer C; Egger T
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():323-4. PubMed ID: 19803008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.
    Hoepelman AI; Kieft H; Aoun M; Kosmidis J; Strand T; Verhoef J; Gillespie SH; Riddell J; Varghese G; Meunier F
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():175-86. PubMed ID: 8150761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime in severe infections: a Swiss multicentre study.
    Francioli P; Clément M; Geroulanos S; von Graevenitz A; Luthy R; Regamey C; Stalder H; Vogt M; Waldvogel FA
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():139-46. PubMed ID: 6225761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ceftazidime in patients with liver cirrhosis and ascites.
    el Touny M; el Guinaidy MA; Abd el Barry M; Osman L; Sabbour MS
    J Antimicrob Chemother; 1991 Jul; 28(1):95-100. PubMed ID: 1769947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of ceftazidime in severe Gram-negative infections--a preliminary study.
    Clumeck N; Vanlaethem Y; Gordts B; Jaspar N; Butzler JP
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():317-21. PubMed ID: 19803007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies of ceftazidime in serum, bone, bile, tissue fluid and peritoneal fluid.
    Wittmann DH; Schassan HH; Kohler F; Seibert W
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():293-7. PubMed ID: 19803001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections.
    Giamarellou H; Perdikaris G; Galanakis N; Davoulos G; Mandragos K; Sfikakis P
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1362-7. PubMed ID: 2679374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
    Colardyn F
    J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
    Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
    Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers.
    Wise ER; Armstrong GC; Brown RM; Andrews JM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():277-82. PubMed ID: 19802998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.
    Clumeck N; Van Laethem Y; Gordts B; Jaspar N; Butzler JP
    Antimicrob Agents Chemother; 1983 Aug; 24(2):176-80. PubMed ID: 6357068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].
    Prévotat A; Leroy S; Perez T; Wallet F; Wallaert B
    Rev Mal Respir; 2010 May; 27(5):449-56. PubMed ID: 20569877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections.
    Chaudhary M; Shrivastava SM; Sehgal R
    Curr Clin Pharmacol; 2009 Jan; 4(1):62-6. PubMed ID: 19149503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.